C
Coherus Oncology, Inc. (CHRS)
NGM – Real Time Price. Currency in USD
1.71
-0.24 (-12.31%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
1.71
-0.24 (-12.31%)
At close: May 12, 2026, 4:00 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 1.47 | 6.05 | 7.0 | |
| Quick ratio | 1.45 | 5.63 | 7.0 | |
| Debt to Equity | 0.89 | 0.30 | 6.0 | |
| Debt to Assets | 0.20 | 1.04 | 8.0 | |
| Interest coverage | -20.40 | -16.91 | 1.0 | |
| Weighted average score | 5.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 211M | 257M | 26M | 42M | 42M |
| Gross Profit | 137M | 94M | 12M | 24M | 24M |
| Operating Income | -257M | -193M | -193M | -180M | -179M |
| Net Income | -292M | -238M | -148M | -170M | -170M |
| EBITDA | -253M | -189M | -188M | -176M | -175M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 88.72 | 35.77 | 10 |
| Next quarter | 124.36 | 32.48 | 10 |
| Current year | 100.07 | 38.26 | 10 |
| Next year | 33.26 | 4.82 | 7.0 |
| Weighted average score | 9.3 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 10.17 | -6.17 | -25.8 | 57.45 | 4.8 |
| Y/Y | 64.85 | 26.38 | 11.36 | -168.91 | 7.0 |
| 3y average | -2.67 | 13.74 | -193.79 | -153.78 | 2.8 |
| 5y average | -14.94 | -55.49 | -183.04 | -223.13 | 1.0 |
| Weighted average score | 3.9 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $88.9M significantly exceed its total debt $54.4M, ensuring strong financial flexibility
Total current assets $206.7M exceed Total current liabilities $140.4M, highlighting excellent liquidity
Debt-to-equity ratio (0.9) is near the industry average, reflecting balanced leverage
Interest coverage ratio (-20.4x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$19.7M limits the company's ability to reinvest or pay down debt